|
1
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu Z: Nonmetabolic functions of pyruvate
kinase isoform M2 in controlling cell cycle progression and
tumorigenesis. Chin J Cancer. 31:5–7. 2012.PubMed/NCBI
|
|
3
|
Anastasiou D, Poulogiannis G, Asara JM,
Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW,
Auld DS, et al: Inhibition of pyruvate kinase M2 by reactive oxygen
species contributes to cellular antioxidant responses. Science.
334:1278–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Christofk HR, Vander Heiden MG, Wu N,
Asara JM and Cantley LC: Pyruvate kinase M2 is a
phosphotyrosine-binding protein. Nature. 452:181–186. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gomez-Escudero J, Clemente C, Garcia-Weber
D, Acín-Pérez R, Millán J, Enríquez JA, Bentley K, Carmeliet P and
Arroyo AG: PKM2 regulates endothelial cell junction dynamics and
angiogenesis via ATP production. Sci Rep. 9:150222019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Y, Zhai H, Ouyang Y, Lu Z, Chu C, He Q
and Cao X: Knockdown of PKM2 enhances radiosensitivity of cervical
cancer cells. Cancer Cell Int. 19:1292019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu VM, Howell AJ, Hosios AM, Li Z,
Israelsen WJ and Vander Heiden MG: Cancer-associated mutations in
human pyruvate kinase M2 impair enzyme activity. FEBS Lett.
594:646–664. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta V and Bamezai RN: Human pyruvate
kinase M2: A multifunctional protein. Protein Sci. 19:2031–2044.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kress S, Stein A, Maurer P, Weber B,
Reichert J, Buchmann A, Huppert P and Schwarz M: Expression of
hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol.
124:315–320. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar Y, Tapuria N, Kirmani N and Davidson
BR: Tumour M2-pyruvate kinase: A gastrointestinal cancer marker.
Eur J Gastroenterol Hepatol. 19:265–276. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schneider J and Schulze G: Comparison of
tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen
(CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis
of gastrointestinal cancer. Anticancer Res. 23:5089–5093.
2003.PubMed/NCBI
|
|
12
|
Zhang B, Chen JY, Chen DD, Wang GB and
Shen P: Tumor type M2 pyruvate kinase expression in gastric cancer,
colorectal cancer and controls. World J Gastroenterol.
10:1643–1646. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hathurusinghe HR, Goonetilleke KS and
Siriwardena AK: Current status of tumor M2 pyruvate kinase (tumor
M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg
Oncol. 14:2714–2720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ogawa H, Nagano H, Konno M, Eguchi H,
Koseki J, Kawamoto K, Nishida N, Colvin H, Tomokuni A, Tomimaru Y,
et al: The combination of the expression of hexokinase 2 and
pyruvate kinase M2 is a prognostic marker in patients with
pancreatic cancer. Mol Clin Oncol. 3:563–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Shen L, Chen X, Qian Y, Zhou Q,
Wang Y, Li K, Liu M, Zhang S and Huang X: High expression of PKM2
as a poor prognosis indicator is associated with radiation
resistance in cervical cancer. Histol Histopathol. 30:1313–1320.
2015.PubMed/NCBI
|
|
16
|
Schneider J, Morr H, Velcovsky HG, Weisse
G and Eigenbrodt E: Quantitative detection of tumor M2-pyruvate
kinase in plasma of patients with lung cancer in comparison to
other lung diseases. Cancer Detect Prev. 24:531–535.
2000.PubMed/NCBI
|
|
17
|
Hegele A, Varga Z, Kosche B, Stief T,
Heidenreich A and Hofmann R: Pyruvate kinase type tumor M2 in
urological malignancies. Urol Int. 70:55–58. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ugurel S, Bell N, Sucker A, Zimpfer A,
Rittgen W and Schadendorf D: Tumor type M2 pyruvate kinase
(TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer.
117:825–830. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lüftner D, Mesterharm J, Akrivakis C,
Geppert R, Petrides PE, Wernecke KD and Possinger K: Tumor type M2
pyruvate kinase expression in advanced breast cancer. Anticancer
Res. 20((6D)): D5077–D5082. 2000.
|
|
20
|
Lin Y, Lv F, Liu F, Guo X, Fan Y, Gu F, Gu
J and Fu L: High expression of pyruvate kinase M2 is associated
with chemosensitivity to epirubicin and 5-fluorouracil in breast
cancer. J Cancer. 6:1130–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi HS, Li D, Zhang J, Wang YS, Yang L,
Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts
in mice. Cancer Sci. 101:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martinez-Balibrea E, Plasencia C, Ginés A,
Martinez-Cardús A, Musulén E, Aguilera R, Manzano JL, Neamati N and
Abad A: A proteomic approach links decreased pyruvate kinase M2
expression to oxaliplatin resistance in patients with colorectal
cancer and in human cell lines. Mol Cancer Ther. 8:771–778. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shiragami R, Murata S, Kosugi C, Tezuka T,
Yamazaki M, Hirano A, Yoshimura Y, Suzuki M, Shuto K and Koda K:
Enhanced antitumor activity of cerulenin combined with oxaliplatin
in human colon cancer cells. Int J Oncol. 43:431–438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gelibter AJ, Caponnetto S, Urbano F,
Emiliani A, Scagnoli S, Sirgiovanni G, Napoli VM and Cortesi E:
Adjuvant chemotherapy in resected colon cancer: When, how and how
long? Surg Oncol. 30:100–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petrelli F, Ghidini A and Zaniboni A:
Cetuximab in association with an oxaliplatin-based chemotherapy as
first-line treatment of metastatic colorectal cancer. Recenti Prog
Med. 108:128–135. 2017.(In Italian). PubMed/NCBI
|
|
26
|
Woynarowski JM, Faivre S, Herzig MC,
Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A,
Varchenko M and Juniewicz PE: Oxaliplatin-induced damage of
cellular DNA. Mol Pharmacol. 58:920–927. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goldberg MS and Sharp PA: Pyruvate kinase
M2-specific siRNA induces apoptosis and tumor regression. J Exp
Med. 209:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Badur MG, Divakaruni AS, Parker
SJ, Jäger C, Hiller K, Murphy AN and Metallo CM: Distinct metabolic
states can support self-renewal and lipogenesis in human
pluripotent stem cells under different culture conditions. Cell
Rep. 16:1536–1547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(T)(-Delta Delta C) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wils J: Adjuvant treatment of colon
cancer: Past, present and future. J Chemother. 19:115–122. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Deng S, Yang Y, Han Y, Li X, Wang X, Li X,
Zhang Z and Wang Y: UCP2 inhibits ROS-mediated apoptosis in A549
under hypoxic conditions. PLoS One. 7:e307142012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ju HQ, Lu YX, Wu QN, Liu J, Zeng ZL, Mo
HY, Chen Y, Tian T, Wang Y, Kang TB, et al: Disrupting
G6PD-mediated Redox homeostasis enhances chemosensitivity in
colorectal cancer. Oncogene. 36:6282–6292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stanton RC: Glucose-6-phosphate
dehydrogenase, NADPH, and cell survival. IUBMB Life. 64:362–369.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang W, Xia Y, Ji H, Zheng Y, Liang J,
Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin
transactivation upon EGFR activation. Nature. 480:118–122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee J, Kim HK, Han YM and Kim J: Pyruvate
kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4
in regulating transcription. Int J Biochem Cell Biol. 40:1043–1054.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohkouchi S, Block GJ, Katsha AM, Kanehira
M, Ebina M, Kikuchi T, Saijo Y, Nukiwa T and Prockop DJ:
Mesenchymal stromal cells protect cancer cells from ROS-induced
apoptosis and enhance the Warburg effect by secreting STC1. Mol
Ther. 20:417–423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun Q, Chen X, Ma J, Peng H, Wang F, Zha
X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of
rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is
critical for aerobic glycolysis and tumor growth. Proc Natl Acad
Sci USA. 108:4129–4134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kosugi M, Ahmad R, Alam M, Uchida Y and
Kufe D: MUC1-C oncoprotein regulates glycolysis and pyruvate kinase
M2 activity in cancer cells. PLoS One. 6:e282342011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo W and Semenza GL: Pyruvate kinase M2
regulates glucose metabolism by functioning as a coactivator for
hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2:551–556.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Luo W, Hu H, Chang R, Zhong J, Knabel M,
O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is
a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell.
145:732–744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wheaton WW and Chandel NS: Hypoxia. 2.
Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol.
300:C385–C393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H,
Zha Z, Liu Y, Li Z, Xu Y, et al: Acetylation targets the M2 isoform
of pyruvate kinase for degradation through chaperone-mediated
autophagy and promotes tumor growth. Mol Cell. 42:719–730. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu
A, Fang W, Zhang X, Li Z and Xie K: PKM2 regulates neural invasion
of and predicts poor prognosis for human hilar cholangiocarcinoma.
Mol Cancer. 14:1932015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ginés A, Bystrup S, Ruiz de Porras V,
Guardia C, Musulén E, Martínez-Cardús A, Manzano JL, Layos L, Abad
A and Martínez-Balibrea E: PKM2 subcellular localization is
involved in oxaliplatin resistance acquisition in HT29 human
colorectal cancer cell lines. PLoS One. 10:e01238302015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Solaini G, Baracca A, Lenaz G and Sgarbi
G: Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys
Acta. 1797:1171–1177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Collins P, Jones C, Choudhury S, Damelin L
and Hodgson H: Increased expression of uncoupling protein 2 in
HepG2 cells attenuates oxidative damage and apoptosis. Liver Int.
25:880–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
